ABSTRACT
Noninferiority clinical trials have become standard in the development of new drugs, biologics, and devices. When a placebo-controlled trial is impossible due to the ethical or practical limitations of not treating a medical condition with effective available therapy, a novel product can be indirectly demonstrated to be effective by demonstrating the efficacy is similar to, or better than, that of a known effective treatment, the active control.
